Drug intelligence / Profile preview

TAK-510

Development stage: Phase 1
Lead developer: Takeda
Modality: Small Molecules
Administration: Subcutaneous

Overview

TAK-510 is an investigational small molecule drug developed by Takeda for the treatment of nausea and vomiting. It has been evaluated in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics (PK), and immunogenicity in healthy adult volunteers. The drug is administered subcutaneously, with studies involving both single and multiple dosing regimens. As of now, the precise mechanism of action for TAK-510 remains unknown. There are no approved indications or known adverse events reported for this compound.

Beyond the preview

Go deeper on TAK-510.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-510.

Explore the full profile